Atlas Trials

C3 Glomerulopathy

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch C3 Glomerulopathy

RecordFirmDate
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (NCT05083364)Arrowhead Pharmaceuticals2022-02-01
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127)Apellis Pharmaceuticals, Inc.2021-11-12
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NCT04572854)Apellis Pharmaceuticals, Inc.2021-09-07
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (NCT04183101)Region Skane2020-10-01
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN (NCT03955445)Novartis Pharmaceuticals2019-10-03
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study (NCT03723512)Mario Negri Institute for Pharmacological Research2018-12-06
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 (NCT03459443)Alexion Pharmaceuticals, Inc.2018-06-20
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) (NCT03369236)Alexion Pharmaceuticals, Inc.2018-06-12
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN (NCT03124368)Alexion Pharmaceuticals, Inc.2017-08-09
National Registry of Rare Kidney Diseases (NCT06065852)UK Kidney Association2009-11-06
C3G/Primary IC-MPGN EAP (NCT04729062)Apellis Pharmaceuticals, Inc.

Track C3 Glomerulopathy automatically

Every clearance here is in the API, with alerts when new ones post.